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and increased Fn expression is associated 
with multiple cancers.[5] During breast 
cancer progression, fibrillar Fn (fFn) pro-
motes tumorigenesis and metastasis, 
partly due to an epithelial-to-mesenchymal 
transition (EMT) in malignant cells.[6] Fur-
thermore, upregulation of Fn has been 
identified to be a key step during pre-met-
astatic niche formation.[7]
A mechanosensitive protein, Fn exists 
in a compact state when solubilized 
such as in blood plasma, and in various 
stretched states such as fFn when local-
ized in ECM.[4,8] The structure and con-
formation of Fn governs the exposure 
or sequestration of binding sites that 
impact its biological function and cell 
response.[8b,9] Fn fibrillogenesis involves 
unfolding of the protein via mechanical 
translocation of integrins bound to cell 
surface receptors. Structurally, unfolding 
occurs largely at the mechanosensitive 
type III domain (Fn-3) exposing self-asso-
ciation sites for subsequent fibrillogenesi
s.[4,8b,10] Despite years of study, a compre-
hensive understanding of each region of 
the type I, II, and III Fn domains and how they interact with 
one another or cells to govern fibril formation is still a topic of 
ongoing research.[11]
We discovered that hydrodynamically induced fibrillogen-
esis at the three-phase contact line between air, an Fn solution, 
and a tessellated porous scaffold yields remarkably stable fFn 
Extracellular matrix (ECM) proteins, and most prominently, fibronectin (Fn), 
are routinely used in the form of adsorbed pre-coatings in an attempt to 
create a cell-supporting environment in both two- and three-dimensional 
cell culture systems. However, these protein coatings are typically 
deposited in a form which is structurally and functionally distinct from 
the ECM-constituting fibrillar protein networks naturally deposited by 
cells. Here, the cell-free and scalable synthesis of freely suspended 
and mechanically robust three-dimensional (3D) networks of fibrillar 
fibronectin (fFn) supported by tessellated polymer scaffolds is reported. 
Hydrodynamically induced Fn fibrillogenesis at the three-phase contact line 
between air, an Fn solution, and a tessellated scaffold microstructure yields 
extended protein networks. Importantly, engineered fFn networks promote 
cell invasion and proliferation, enable in vitro expansion of primary cancer 
cells, and induce an epithelial-to-mesenchymal transition in cancer cells. 
Engineered fFn networks support the formation of multicellular cancer 
structures cells from plural effusions of cancer patients. With further work, 
engineered fFn networks can have a transformative impact on fundamental 
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The extracellular matrix (ECM) constitutes the proteinaceous 
microenvironment of all multicellular tissues[1] and serves as a 
model for three-dimensional (3D) in vitro cell culture design.[2] 
Changes in ECM structure and composition drive biological 
function in both healthy and diseased states.[3] Fibronectin (Fn) 
is one of the most abundant ECM proteins in normal tissues,[4] 
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networks that promote cell invasion and proliferation, enable in 
vitro expansion of primary cancer cells, and induce EMT. These 
engineered fFn networks can serve as an engineering platform 
for the design of in vitro 3D culture systems, including tumor 
models which would impact fundamental studies of tumorigen-
esis and advance our ability to directly expand primary patient 
cancer cells.
The cell-free synthesis of scalable, mechanically robust 3D 
networks of fFn suspended across a scaffold support would 
constitute a critical technological advance in engineered 
biomaterials systems. Cell-free fibrillogenesis has been previ-
ously observed by simple shearing of Fn solution, drawing 
of individual fibers,[12] extraction of fibrillar mats[13] from Fn 
solutions, or through the use of mechanical,[14] or interfacially 
active denaturants.[4,14,15] However, these methods suffer from 
several limitations including manual positioning of protein 
fibers or networks,[12,13] low throughput,[12] or the need to chemi-
cally crosslink the protein to ensure fiber stabilization.[13b] In 
application to cell culture and cell analyses, these methods often 
lack: i) effective cell invasion and cell removal capabilities,[13a] 
ii) transparency for microscopy techniques,[4,12,13] iii) a support 
where cells can deposit their own matrix or remain adhered after 
degrading the original protein matrix,[13a,16] and iv) sufficiently 
large areas (≥ 0.2 mm2) of 3D space free of synthetic material. 
When polymer scaffolds are used to mediate some of these 
shortcomings, the support material itself can act as a barrier for 
cell invasion and uninterrupted transport of nutrients.[2,4,12,14,15] 
In contrast, we found that gentle shearing (angular velocity 
of 8 rpm) of an Fn solution at the three-phase contact line 
defined by the protein solution, air, and a support comprised of 
tessellated 500 × 500 µm square pores yields insoluble networks 
of fFn, even in the absence of denaturants (Figure 1). Fn used 
in this study was commercially available, purified Fn isolated 
from blood plasma. The tessellated microfiber scaffolds were 
prepared from poly(lactide-co-glycolide) (PLGA) by 3D jet 
writing.[17] While the scaffold size, pore geometries, and 
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Figure 1. Hydrodynamically induced fibrillogenesis of Fn. a) Fluid shear is applied at the three-phase interface of a porous scaffold, air, and an Fn 
solution resulting in the deposition of a network of insoluble Fn fibrils (fFn) suspended across the scaffold, i.e., fFn networks. b) Polymer microfiber 
scaffolds fabricated via 3D jet writing featuring tessellated square pores. Scale bars 500 µm (left) and 25 µm (inset). c) High-resolution SEM of fFn 
freely suspended within a pore of the scaffold. Scale bar 1 µm. d) Left) LSCM of fFn (green) suspended within the scaffold (blue) for comparison to 
right) Fn deposited by human mammary fibroblasts cultured on glass and subsequently decellularized. Scale bar 25 µm. e) NIH-3T3 mouse fibroblasts 
cultured three days on either left) an fFn network or right) Fn statically adsorbed onto a scaffold. Insets show representative images of the morphology 
and distribution of Fn (green) deposited on scaffolds (blue) either by hydrodynamic shearing at the three-phase interface left inset) or static adsorption 
right inset). Channels: blue, tessellated scaffold; green, Fn; cyan, cell nucleus; and red, actin. Scale bars 500 µm.
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thickness are tunable, all scaffolds used in this study spanned an 
area of 34.8 mm2 featuring square pores with a free volume of 
96% and an overall thickness of 0.12 mm (Figure 1b). The thick-
ness of the engineered fFn networks was chosen for optimal 
imaging results and to allow cells to perfuse in or out, while pro-
viding large volumes of freely suspended protein matrix for cell 
growth in three dimensions. The fFn networks were mechani-
cally robust for easy handling during culture, and readily imple-
mented by standard cell culture techniques in a multiwell plate.
Within 15 min, hydrodynamically induced fibrillogenesis 
resulted in emerging networks of insoluble Fn fibrils that 
extended across the entire scaffold at lengths approaching sev-
eral millimeters (Figure 1c, and Figure S1b–d,f, Supporting 
Information). The absence of a shear force (Figure S1f, Sup-
porting Information and insets of Figure 1e), or hydrodynamic 
shearing over a smooth, non-porous support (Figure S1a, Sup-
porting Information) did not result in fibrillar networks. We 
instead observed a conformal Fn coating. The total amount of 
Fn loaded onto a single scaffold by hydrodynamically induced 
fibrillogenesis was 12-fold higher than the amount of protein 
detected for conformally coated scaffolds (Figure S1e, Sup-
porting Information). The fFn networks displayed morpho-
logical similarities to matrix deposited by human fibroblasts 
(Figure 1d, and Figure S2a,b, Supporting Information).
Engineered fFn networks proved to be insoluble in a 1% 
deoxycholate solution (Figure S3, Supporting Information), 
another feature of biologically derived Fn matrix.[18] Impor-
tantly, fFn networks supported confluent cell culture that 
extended throughout the entire scaffold volume (Figure 1e, 
and Figure S4, Supporting Information). In contrast, identical 
scaffolds that were conformally coated with Fn did not promote 
continuous cell coverage of the open pore areas (Figure 1e). 
A wide range of mammalian cell types including normal cells 
(fibroblast and endothelial cells), cancer cells (breast and pan-
creatic cancer cells), and mesenchymal stem cells[17] formed 
confluent 3D cell cultures in as little as three days (Figure 1e, 
and Figures S4 and S5, Supporting Information).
Engineered fFn networks, but not conformally deposited 
Fn, stained positively with an Fn-3 antibody indicating exposed 
cellular Fn after hydrodynamic fibrillogenesis (Figures S6 and 
S2b, Supporting Information). This resembled the staining 
of Fn deposited by human mammary fibroblasts (Figure S2a, 
Supporting Information, stained after removal of the cells). In 
contrast, statically adsorbed Fn on either tessellated scaffolds 
or tissue culture polystyrene (TCPS) was not recognized by 
the Fn-3 antibody (Figure S2c,d, Supporting Information). For 
further validation, an IST-9 antibody was used since its speci-
ficity to the alternatively spliced domain A (EIIIA or EDA), a 
cellular Fn variant within the type III region of Fn, is well docu-
mented.[19] When directly comparing engineered fFn networks 
to Fn statically deposited onto non-woven mats (a scaffold of 
randomly deposited PLGA fibers), we found that the Fn-3 and 
IST-9 antibodies only recognized the fFn networks and not the 
Fn conformally deposited onto non-woven mats (Figure S7, Sup-
porting Information).[19a] To definitively confirm the presence of 
EDA(+) Fn in our protein source, liquid chromatography mass 
spectrometry-based (LC-MS) proteomics was performed. As 
expected, the main constituent was Fn with 71–82% sequence 
coverage (Figure S8c, Supporting Information). Annotated 
MS/MS spectra for tryptic EDA peptides GLAFTDVDVDSIK 
and IAWESPQGQVSR are shown in Figure S8a,b in the Sup-
porting Information. The EDA fragments are expected to be 
identified after trypsin digestion and indeed were identified 
with nearly complete sequencing, confirming the presence of 
EDA(+) Fn in our protein source. Although, plasma Fn isoforms 
are the main constituent of Fn in blood plasma, previous studies 
have reported that small fractions of cellular Fn can circulate in 
the blood of healthy patients.[20]
Collectively, these data suggest that EDA(+) Fn within our 
protein source is physically exposed only after hydrodynamic 
fibrillogenesis, and is not available for antibody binding when 
Fn is conformally adsorbed onto a surface. We note that the role 
of the EDA peptide in Fn biology is a topic of ongoing research. 
While this variant is not believed to be a requisite for fibrillo-
genesis,[21] some studies have shown it plays an important role 
by leading to more robust fibrillar networks secreted by cells.[22] 
Additionally, while some report recombinant EDA(+) Fn coated 
onto a surface may enhance cell migration,[23] other studies 
have suggested that knockdown of EDA-Fn secretion impedes 
cell motility even on Fn-coated substrates.[24] Missirlis et al. dis-
cuss potentially conflicting results researchers have reported 
with respect to the role of EDA-Fn in cell motility.[24] Finally, the 
mechanosensitivity of the EDA domain is not well known[25] 
and warrants further investigation. Hence, it is reasonable that 
changes in Fn binding activity may occur when Fn is presented 
in a fibrillar state compared to a conformal surface coating, 
which has not yet been directly investigated. These many 
unknowns underscore the need for a native-like fFn cell culture 
platform. We thus concluded that our Fn fibril production and 
characterization results are consistent with a mechanism where 
interfacial shearing induces mechanical deformation of solute 
Fn that extends the protein, enabling self-polymerization, and 
fiber formation. This is analogous to the mechanically induced 
unfolding of the Fn molecule during cell-driven,[9b,26] as well as 
previously reported shear-driven fibrillogenesis.[4,8a,27] In con-
trast to the widely used conformal Fn pre-coatings, hydrody-
namically induced fibrillogenesis not only results in a stable, 
fibrillar matrix readily applicable to 3D cell culture, but also 
provides access to ECM mimicries with biologically distinct 
properties.[10a,28]
Recognizing the prominence of Fn in primary breast cancer 
ECM,[29] we tested the ability of fFn networks to enhance tumor 
engraftment of breast cancer cells in a murine model of epithelial 
breast cancer. We cultured AT-3 murine breast cancer cells that 
stably expressed firefly luciferase[30] onto fFn networks. After 
three days, cells had infiltrated the entire scaffold (Figure 2a,b, 
and Figure S9a,b, Supporting Information), while still remaining 
in a proliferative state (Figure S9c, Supporting Information).
The fFn networks carrying 30 000 cells per scaffold were 
orthotopically implanted into immunocompetent C57BL/6 
mice. Bioluminescence imaging revealed initial signs of tumo-
rigenesis as early as two days after implantation (Figure S10, 
Supporting Information). For comparison, the cell suspension 
of an equivalent number of AT-3 cells did not support tumor 
engraftment over 21 d (Figure 2c, and Figure S10, Supporting 
Information). Histology of engrafted tumors confirmed nat-
ural invasion of cancer cells from the fFn networks into adja-
cent tissue (Figure 2d). Pre-seeded with 30 000 AT-3 cells, fFn 
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Figure 2. Engineered fFn networks enhance tumor engraftment efficiency in a mouse breast cancer model. a) AT-3 mouse breast cancer cells 
formed 3D cell volumes approximately 70 µm thick in vitro after three days on fFn networks. Scale bar 25 µm. b) Large-scale view shows that 
AT-3 cells in (a) proliferated and filled the 3D space within the fFn network. Scale bar 500 µm. a,b) Channels: cyan, cell nucleus; red, actin. 
c) Bioluminescence image of tumor formation in immune-competent mice 21 d after AT-3 cells were orthotopically implanted (image exposure 
time 10 s). Mice on the left after implantation of fFn networks carrying about 30 000 AT-3 cells into the mammary fat pads indicated by arrows 
(group 1). The contralateral mammary fat pad received an injection of approximately the same number of cells suspended in an Fn solution 
as indicated by circles (group 2). The mouse on the right is a positive control having received the group 3 fFn network in the left mammary 
fat pad (arrow), and the group 4 injection in the right, each delivering 200 000 AT-3 cells (the minimum required for tumor formation by cell 
injection[30]). d) Mason’s Trichrome staining of a group 1 tumor graft that formed after 21 d showing AT-3 cells invading the surrounding tis-
sues. Scale bar: 25 µm. e,f ) Quantification of the CD29+/CD24+ population in AT-3 cells capable of self-renewal (P < 0.05) (e) and the CD29+/
CD24+/CD90.2+ tumor initiating population in AT-3 cells (f ). AT-3 cells were cultured three days on TCPS, TCPS with Fn conformally adsorbed 
(Fn on TCPS), or fFn networks. A single star indicates that the fFn networks are statistically different from TCPS and Fn on TCPS; a double star 
indicates that TCPS and Fn on TCPS are statistically similar.
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networks showed robust tumor engraftment at cell numbers 
that were 85% lower than what is typically needed for successful 
engraftment.[30] The increased tumorigenicity is consistent with 
our in vitro findings that AT-3 cells cultured on fFn networks 
have increased subpopulations of tumor-initiating (CD29+/
CD24+)[31] and metastatic (CD29+/CD24+/CD90.2+)[31c,32] cells 
(Figure 2e,f). We further note that the invasive subpopulation 
(CD90.2+) was nearly 30-fold higher on fFn networks relative to 
Fn-coated TCPS (Figure S9d, Supporting Information).
We next evaluated if the increased tumorigenicity observed 
in mouse breast cancer cells would also be observed in human 
triple negative breast cancer cells. We selected the MDA-MB-
468 cell line because less than 3% of the total population 
express the CD44+/CD24− tumor initiating phenotype.[33] After 
four days of expansion on fFn networks, MDA-MB-468 cells 
formed a dense 3D cancer microenvironment over extended 
areas of about 10 mm2 (Figure 3a,b, and Figure S11a, Sup-
porting Information). Compared to cells cultured on either 
TCPS or Fn-coated TCPS, the CD44+/CD24− subpopulation 
was significantly higher on fFn networks (Figure 3c). In addi-
tion, the CD44+/CD24−/ALDH+ subpopulation significantly 
increased on fFn networks relative to the control groups for all 
time points (Figure 3d). CD44+/CD24−/ALDH+ breast cancer 
cells have higher tumor-initiating potential than either CD44+/
CD24− or ALDH+ populations (ALDH, aldehyde dehydroge-
nase).[34] Because the ALDH+ subpopulation showed no signifi-
cant difference relative to the controls after four days in culture 
on fFn networks (Figure S11b, Supporting Information), the 
data indicate that enrichment of CD44+/CD24−/ALDH+ cells is 
largely driven by an increase in the CD44+/CD24− subpopula-
tion. These data are consistent with an increased level of EMT 
in MDA-MB-468 cells after expansion on fFn networks relative 
to the control groups (Figure 3c, and Figures S11 and S12, 
Supporting Information).
Stem-like breast cancer cells can secrete extracellular 
laminin during matrix remodeling to improve self-renewal and 
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Figure 3. Engineered fFn networks increase the tumor-initiating population in MDA-MB-468 human breast cancer cells. a) MDA-MB-468 breast cancer 
cells cultured four days on fFn networks form cell–cell and cell–ECM contacts. Scale bar 25 µm. b) MDA-MB-468 cells form large interconnected 
volumes throughout fFn networks after four days. Scale bar 500 µm. a,b) Channels: green, Fn; orange, laminin; cyan, cell nucleus; and red, actin. 
c,d) Population of MDA-MB-468s on fFn networks (black solid line and square marker), TCPS (black dotted line and crisscross marker), or Fn adsorbed 
conformally onto TCPS (gray line and triangular marker) that are CD44+/CD24− (c) and CD44+/CD24−/ALDH+ (d) measured at different culture time 
points. Marker expression for cells on TCPS or Fn on TCPS is significantly lower than that of the fFn network at values nearing zero in d). The starred 
time point is statistically different from the other three time points within the fFn network data set.
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Figure 4. Engineered fFn networks enable expansion of patient breast cancer cells and enrich the tumor-initiating cell population in an EMT. 
a,b) Four-day culture of heterogenous cell populations from Patient E on fFn networks. Channels: cyan, cell nucleus; red, actin; and yellow, cytokeratin 5. 
a) 3D cell structures form within the pores and along the microfiber walls of the scaffold. Scale bar 25 µm. b) Patient E cells fill the fFn networks at a 
large scale across all square 500 µm-wide pores of the tessellated scaffold. Scale bar 500 µm. c) Patient cell proliferation measured via mitochondrial 
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tumorigenicity.[35] With the observed enrichment of CD44+/
CD24− and CD44+/CD24−/ALDH+ in MDA-MB-468 cells after 
culture on fFn networks, we asked whether significant amounts 
of endogenous laminin had been incorporated into the ECM, 
influencing cell phenotype. After four days of MDA-MB-468 
cell culture, fFn networks were decellularized[36] and co-stained 
for Fn and laminin. MDA-MB-468 cells had only secreted 
small and sporadic amounts of laminin, while the original fFn 
network remained intact (Figure S13, Supporting Information). 
This experiment indicates that Fn is the predominant ECM 
factor for early EMT transitions on engineered fFn networks.
Facile, reliable expansion of patient-derived breast cancer 
cells would tremendously advance precision oncology, but still 
remains an elusive goal.[37] Mouse tumor xenografts have been 
used to develop avatars using primary human patient cells, but 
in breast cancer, this approach suffers from poor cell engraft-
ment and limited cell proliferation.[37b,38] We therefore evaluated 
fFn networks as a platform to directly expand patient-derived 
cells from malignant pleural effusion or ascites samples from 
14 women representing a range of ages and molecular subtypes 
of metastatic breast cancers (Table S1, Supporting Informa-
tion). We successfully cultured metastatic breast cancer cells 
on fFn networks from all 14 patient samples. Importantly, cell 
expansion on fFn networks did not require prior fractionation 
of the patient samples and resulted in a 36-fold enrichment of 
the cancer cell population (Figure S14a, Supporting Informa-
tion). The majority of patients (9 out of 13; one sample was of 
unknown receptor status) were estrogen receptor positive, a 
breast cancer subtype that typically is less likely to form tumor 
grafts.[33c,37a] Cancer cells from all 14 patient samples prolifer-
ated on fFn networks, but not on TCPS or Fn-coated TCPS, as 
represented in Figure 4c and Figure S15b in the Supporting 
Information. Ki67 staining further indicated that cells were in a 
proliferative state on fFn networks, but senescent on TCPS[37a] 
(Figure 4c). Cells from patient E (patient samples arbitrarily 
named), which were first cultured on fFn networks for one 
day, then removed and re-seeded onto TCPS, proliferated for 
five passages before entering senescence (Figure S15a, Sup-
porting Information). This repeatedly observed finding was 
in stark contrast to the unsuccessful direct culture of patient 
cells on TCPS, suggesting the potential use of fFn networks as 
a preconditioning microenvironment to promote expansion of 
cancer cells from pleural effusions, an accessible, yet underuti-
lized source of patient tumor cells.
The total patient cell population increased by more than seven-
fold relative to the original patient sample over the course of eight 
days of culture on fFn networks (Figure 4c). In general, diverse 
cell populations were maintained on fFn networks showing het-
erogeneity in morphology and expression of cytokeratin 5 (CK5), 
an epithelial marker (Figure 4a,b and Figure S16a–d, Supporting 
Information). After five days of culture, CK5+ cells remained in 
small clusters. By day 10, CK5+ cells had expanded and spread 
out into the open pores of the scaffold (Figure S16d, Supporting 
Information). Different cell types were often found to spatially 
segregate as seen in Figure S16a in the Supporting Informa-
tion, where CK5+ cells formed tight clusters on the fFn while 
actin-rich cells of a spindle-like morphology adhered first to the 
scaffold microfibers and then proliferated outwards.
Because of their distinct receptor status, patient samples 
E, F, and G were selected for evaluation of cancer stem cell 
markers after a six-day culture on fFn networks. Patient 
breast cancer cells with a mesenchymal CD44+/CD24− stem 
cell phenotype were enriched relative to the percent in the 
original sample (Figure 4d,e, and Figure S14c, Supporting 
Information). This finding corroborates earlier results 
with MDA-MB-468 cells (Figure 3c). The epithelial tumor-
initiating subpopulation marked as ALDH+ (Figure 4g, and 
Figure S14b,e, Supporting Information) and the highly tumo-
rigenic overlapping immunotype CD44+/CD24−/ALDH+[39] 
(Figure 4h) were maintained on fFn networks compared to 
the original patient sample (having averages within 10%). 
Additionally, the percentage of cancer cells expressing the 
epithelial marker, EpCAM (epithelial cell adhesion mole-
cule), disappeared after culture on fFn networks (Figure 4f, 
and Figure S14d, Supporting Information). Upregulation 
of mesenchymal stem-like cancer cells combined with 
downregulation of EpCAM and maintenance of the ALDH+ 
subpopulation characterizes an EMT, suggesting that fFn net-
works can induce EMT in breast cancer patient cells cultured 
in vitro. Despite these observed phenotypic changes, the 
breast cancer receptor status of the original sample was main-
tained after the six-day culture on fFn networks (Figure S16e, 
Supporting Information).
Engineered fFn networks represent a major advance 
toward the goal of using cancer patient cells to engineer 
tumor tissue that authentically represents the subtypes, het-
erogeneity, architecture, and patient-to-patient variability of 
breast cancer. This work further suggests that Fn may play 
a role in EMT.[40] Scaffolds functionalized with our scalable 
fFn technology produce suitable microenvironments for 
direct and efficient culture of unfractionated patient sam-
ples. In short-term in vitro culture, fFn networks resulted in 
the expansion of patient samples, where less than 5% of the 
initial population were cancer cells, to complex cultures or 
microtumors with cancer cells constituting 36% of the total 
cell population.
Our results suggest that engineered fFn networks can 
provide the next-generation 3D cell culture platform for expan-
sion of both immortalized and primary cancer cells in vitro. 
Harnessing the known ability of Fn to form fibrils under shear 
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activity is far increased on fFn networks (black solid line and square marker) relative to the little to no growth on Fn adsorbed conformally onto TCPS 
(gray line and triangular marker), or TCPS alone (black dotted line and crisscross marker). Additionally, the inset shows representative images of Ki67 
staining of patient cells cultured on either TCPS or fFn networks. Darker color indicates that the cells are in a proliferative state on fFn networks but 
senescent on TCPS. d) Flow cytometry measurement of CD24 and CD44 in Patient E cells where the original sample is shown in red and the six day 
in vitro culture on fFn networks is shown in blue. Cell phenotype concentrated towards CD44+/CD24− status after culture on fFn networks. e–h) Flow 
cytometry measurements of the percentage of lineage negative cells that are CD44+/CD24− (e), EpCAM+ (epithelial cell adhesion molecule) (f), ALDH+ 
(aldehyde dehydrogenase) (g), and CD44+/CD24−/ALDH+ (h) within samples from patients E, F, and G. Gray bars represent the original patient 
sample and white bars indicate result after cells were cultured on engineered fFn networks for six days.
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forces, we directly suspended fFn across open-pore scaffolds 
resulting in a platform that is readily implemented in cell 
culture. These fFn networks allow cells to craft their own micro-
environment while we observe the cell response, representing a 
transformative technology in fundamental cancer studies,[37b] 
precision medicine,[33c] pharmaceutical development,[37b] and 
pre-clinical screening.[37a]
Experimental Section
Scaffold Fabrication: Tessellated scaffolds were made via 3D jet writing 
as previously described.[17] Briefly, PLGA was dissolved into a 30 wt% 
solution of chloroform and N,N-dimethylformamide at a ratio of 93:7. 
The solution was pumped through a 20 gauge needle at 0.04 mL h–1 
with an applied voltage of 16 kV. As the fluid jet descends to the ground 
electrode, it passes through a copper ring at 9 kV. The jetted fiber is 
collected on the ground electrode, a stainless-steel plate, which is 
translated through x–y coordinates by computer-controlled motions to 
stack the depositing fiber onto itself in a desired pattern. Non-woven 
mats were made by random deposition of electrospun PLGA fibers onto 
a flat grounded electrode without use of the copper ring.
Hydrodynamically Induced Fibrillogenesis and Other Fibronectin 
Substrates: The tessellated scaffold fabricated via 3D jet writing was first 
secured in a custom-built stainless-steel frame. The framed scaffold was 
then placed at the center of a 2-mL microcentrifuge tube containing 
900 µL volume of a 111 µg mL–1 solution of human Fn such that the 
air, scaffold, and solution formed a three-phase interface when the tube 
was laid on its side. The tube was placed on a rotisserie rotator at 30 °C 
and 8 rpm (for an interface velocity of 10.4 mm s–1) for a period of 2 h. 
The protein-loaded scaffold was then washed three times in Dulbecco’s 
phosphate buffered saline (DPBS) and stored at 4 °C up to one week 
until use. For suspended collagen networks, 900 µL of collagen I 
dissolved in 33 × 10−3 m acetic acid at 2.7 mg mL–1 was combined with 
100 µL of Dulbecco’s modified Eagle medium (DMEM) and 140 µL of 
0.34 N NaOH in a 2-mL microcentrifuge tube. The solution turned from 
yellow to pink with the addition of base. All collagen preparations were 
performed on ice. The framed scaffold was then secured in the 2-mL 
tube to form a three-phase interface and rotated for four hours at 27 °C. 
Conformal Fn coatings onto tessellated scaffolds, smooth TCPS surfaces, 
or non-woven fiber mats were prepared by statically submerging the 
substrate in a 111 µg mL–1 Fn solution for 2 h at 30 °C and overnight at 
room temperature (RT).
Protein Mass Measurements: A Micro BCA assay (Pierce Biotechnology, 
Rockford, IL) was used to measure the mass of protein deposited onto 
the scaffolds. First, the PLGA was degraded in a 0.9 m NaOH solution 
for 1 h, and then the solution was neutralized in a 0.9 m HCl solution. 
The mass of protein was determined by measuring the absorption at 
562 nm after a 1 h, 60 °C incubation, in the Micro BCA working reagent 
and referenced to a standard curve of known masses.
ICC Staining: Immunocytochemical (ICC) analysis was performed 
as previously described.[17] Briefly, cells on the fFn networks were fixed 
with a 2% paraformaldehyde overnight. Cells were then permeabilized 
with a 0.1% Triton X-100 solution for 5 min. The fixed cells were then 
exposed to a 5% bovine serum albumin (BSA) blocking solution for 1 h 
before application of the antibodies. Cells were imaged using a Nikon 
A-1 confocal microscope (Nikon Corp., Minato, Tokyo, Japan). If only 
protein without cells was present on the fFn network, then Triton X-100 
was not used.
SEM Imaging: The tessellated scaffold was sputter coated with 
gold and visualized with an Amray FE 1900 scanning electron 
microscope (SEM) with an acceleration voltage of 5 kV. All other 
SEM images were taken with a Helios 650 Nanolab SEM/FIB by FEI 
of Thermo Fisher Scientific at voltages ranging from 2 to 5 kV. Prior 
to SEM, samples of cells or proteins were dehydrated by soaking for 
20 min in a series of ethanol solutions increasing in concentration. The 
sample was then transferred to a microcentrifuge tube and tertbutanol 
was added to cover. The tube was placed in liquid nitrogen for two 
minutes then lyophilized overnight.
Deoxycholate Treatment: fFn networks that were subjected to 
deoxycholate treatment were submerged in 1% deoxycholate solution 
overnight on an orbital shaker. fFn networks that were left untreated 
for comparison to deoxycholate exposure were also rotated overnight 
in water on the orbital shaker. These fFn networks were prepared using 
fluorescent Fn that was first conjugated to DyLight-650 using a DyLight 
antibody labeling kit following manufacturer instructions.
Cell Culture: Malignant pleural effusion and ascites samples from 
women with metastatic breast cancer were collected with written 
informed consent from all subjects under a protocol approved by the 
University of Michigan Institutional Review Board (IRBMED #2001-
0344). These samples were collected for clinical indications, and this 
research used excess fluid samples that otherwise would be discarded. 
Total cells were concentrated in samples by centrifugation without 
additional processing steps prior to seeding onto scaffolds. Breast 
cancer patient cell samples were seeded in 1 mL onto fFn networks 
with square scaffold pores 500 µm wide at a concentration of 2 × 106 
cells mL−1. Cancer cell lines were seeded in 100 µL at a concentration 
of 2 × 106 cells mL−1 for 4 h, then the concentration was diluted to 
2 × 105 cells mL−1. Cells were cultured in DMEM containing 10% 
fetal bovine serum (FBS), 1% non-essential amino acids (NEAA), 
2 × 10−3 m L-glutamine, and 1% antibiotic–antimycotic. Cells were 
seeded and cultured in low adhesion 24 well plates (Corning Inc., 
Corning, NY, USA) and maintained at 37 °C in 5% CO2. Although not 
always passaged, passaging primary lineage negative cancer cells could 
be done by placing a cell-free fFn network in contact overnight with 
another that had already grown confluent with cells.
Proteomics: Lyophilized Fn (Corning) was dissolved in DPBS as 
described above. The protein concentration was determined by Qubit 
fluorometry (Invitrogen). 10 µg of the sample was processed by sodium 
dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) using a 
10% Bis-Tris NuPage mini-gel with the 3-(N-morpholino)propanesulfonic 
acid (MOPS) buffer system. The mobility region was excised and 
processed by in-gel digestion using a robot (ProGest, DigiLab) using the 
following procedure: washed with 25 × 10−3 m ammonium bicarbonate 
followed by acetonitrile, reduced with 10 × 10−3 m dithiothreitol at 
60 °C followed by alkylation with 50 × 10−3 m iodoacetamide at RT, 
digested with sequencing grade trypsin (Promega) at 37 °C for 4h, and 
quenched with formic acid. Then the supernatant was analyzed directly 
without further processing. Half of the gel digest was analyzed by nano 
LC-MS/MS with a Waters NanoAcquity HPLC system interfaced to a 
ThermoFisher Q Exactive. Peptides were loaded on a trapping column 
and eluted over a 75 µm analytical column at 350 nL min−1; both 
columns were packed with Luna C18 resin (Phenomenex). The mass 
spectrometer was operated in data-dependent mode, with the Orbitrap 
operating at 70 000 and 17 500 FWHM for MS and MS/MS respectively. 
The fifteen most abundant ions were selected for MS/MS. Data were 
searched using a local copy of Mascot (Matrix Science) with the 
following parameters: Enzyme:Trypsin/P; Database:SwissProt Human 
(concatenated forward and reverse plus common contaminants); Fixed 
modification: Carbamidomethyl (C); Variable modifications: none; mass 
values: monoisotopic; peptide mass tolerance: 10 ppm; fragment mass 
tolerance: 0.02 Da; maximum. missed cleavages: 2. Mascot dat-files 
were parsed into Scaffold (Proteome Software) for validation, filtering 
and to create a non-redundant protein list. Data were filtered using a 
threshold for the false discovery rate (FDR) of 1% protein and requiring 
at least two unique peptides per protein.
Proliferation Assays: AT-3 mouse breast cancer cells and human breast 
cancer cell lines T47D and SUM159 all stably expressed firefly luciferase. 
Proliferation was tracked over time by administering 15 mg mL−1 
D-luciferin to the cell medium at a ratio of 1:100 and incubating for 10 min 
before the relative light intensity was measured using a luminometer 
(Perkin Elmer MLD2300-000). The growth rates of the primary patient 
samples and the MDA-MB-468 cell line were evaluated by measuring 
changes in mitochondrial activity using a resazurin-based assay kit (Tox-8, 
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Sigma–Aldrich, St. Louis, MO, USA) following the manufacturer guidelines. 
The initial signal was recorded after seeding, and then subsequent 
mitochondrial activity measurements were normalized to the initial time 
point. Additionally, Ki67 staining was used to determine whether the 
primary patient samples were in a proliferative or senescent state.
Decellularization: If cells were removed from fFn networks to visualize 
the remaining protein matrix, samples were decellularized in a protocol 
adapted from Lu et al.[36] Samples were washed with phosphate buffered 
saline (PBS), then deionized (DI) water, and immersed in a solution of 
0.1% Triton X-100 with 1.5 m KCl in 50 × 10−3 m Tris buffer on a slow-
moving shaker for two hours at 4 °C. Samples were washed in 10 × 10−3 m 
Tris buffer, followed by DI water for one hour each. The remaining 
protein matrix was fixed and stained via ICC protocol.
Animal Protocol: All animal studies were approved by the University 
of Michigan Institutional Animal Care and Use Committee. Briefly, 
6–8-week-old female C57BL/6J mice (Charles River Laboratories Inc., 
Wilmington, MA, USA) were anesthetized using 1–2% isoflurane at 
a flowing oxygen rate of 1 L min−1 (EZ150 Isoflurane Vaporizer, EZ 
Anesthesia), and an incision was made to expose the mammary fat 
pad. A fFn network carrying AT-3 cells was then placed directly into 
the fat pad[30] and the incision was closed with wound clips. The 
number of AT-3 cells on the scaffold was verified using luminescence. 
15 mg mL−1 D-luciferin was added to the cell medium at a ratio of 
1:100 and incubated for 10 min before the relative light intensity was 
measured using a luminometer (Perkin Elmer MLD2300-000) and 
compared with a standard curve. Tumor engraftment was evaluated 
using bioluminescence imaging.[30]
Flow Cytometry: Cells were stained following a previously established 
protocol.[39,41] Cells were removed using 0.25% trypsin, which was 
neutralized using a 3:1 volume of complete medium. Cells were 
then counted using a Luna-FL dual fluorescence cell counter (Logos 
Biosystems, Dongan-gu, Anyang-si, Gyueonggi-do, South Korea), and 
re-suspended in aldefluor buffer. Antibodies were added and incubated 
for 30 min, and then rinsed with aldefluor buffer. For primary patient 
sample analysis, the cells were first incubated in the lineage cocktail for 
30 min, before staining for EpCAM, CD44, CD24, and ALDH activity. 
MDA-MB-468 cells were used to establish single color channels. Isotype 
controls were used to establish gating for the CD44, EpCAM, lineage 
negative cells, and CD24.[39,41] N,N-diethylaminobenzaldehyde (DEAB) 
was used to establish gating for the aldefluor activity assay.[39]
Histology: Tumor histology was evaluated by first fixing with 4% 
formalin for 24 h. Then, the tissue was prepared for histology by 
dehydrating in ethanol, sealed with paraffin, and sliced for staining with 
Masson’s trichrome.
Statistics: Statistical analysis was performed using Minitab (Minitab 
Inc., State College, PA, USA). One-way analysis of variance (ANOVA, 
p < 0.05) was used to determine statistical significance. Tukey 
multicomparison testing was performed to determine differences 
between groups. All data were reported as the mean ± standard deviation.
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